A. Bair

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Brian I. Rini, Bohuslav Melichar, Mayer Fishman et al. · Annals of Oncology · 2015 · 75 citations · Full text

Medicine, Oncology, Pharmacology +15

Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.

Brian I. Rini, Viktor Grünwald, Mayer Fishman et al. · Journal of Clinical Oncology · 2012 · 37 citations

Medicine, Oncology, Pharmacology +17

Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC).

Thomas E. Hutson, Vladmir Lesovoy, V.P. Stus et al. · Journal of Clinical Oncology · 2013 · 29 citations

Medicine, Oncology, Pharmacotherapy +10

A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results

Steven Limentani, R. Just, A. Purdham et al. · Journal of Clinical Oncology · 2008 · 18 citations

Pharmacy, Oncology, Pharmacology +17

Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC).

Eric Jonasch, A. Bair, Y. Chen et al. · Journal of Clinical Oncology · 2010 · 17 citations

Medicine, Oncology, Pharmacology +15